{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T02:14:23Z","timestamp":1724292863729},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Royal Society UK","award":["IEC\\NSFC\\201094"],"award-info":[{"award-number":["IEC\\NSFC\\201094"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00011-023-01788-y","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T12:02:35Z","timestamp":1694174555000},"page":"1873-1876","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer\u2019s disease treatment"],"prefix":"10.1007","volume":"72","author":[{"given":"Jinwei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"1788_CR1","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer\u2019s disease. Nat Rev Dis Primers. 2015;1:15056.","journal-title":"Nat Rev Dis Primers"},{"key":"1788_CR2","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1039\/C9CS00199A","volume":"49","author":"PC Ke","year":"2020","unstructured":"Ke PC, Zhou R, Serpell LC, Riek R, Knowles TPJ, Lashuel HA, et al. Half a century of amyloids: past, present and future. Chem Soc Rev. 2020;49:5473\u2013509.","journal-title":"Chem Soc Rev"},{"key":"1788_CR3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nn0901-887","volume":"4","author":"C Nilsberth","year":"2001","unstructured":"Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The \u2018Arctic\u2019 APP mutation (E693G) causes Alzheimer\u2019s disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4:887\u201393.","journal-title":"Nat Neurosci"},{"key":"1788_CR4","doi-asserted-by":"publisher","first-page":"14411","DOI":"10.1523\/JNEUROSCI.3537-10.2010","volume":"30","author":"B O'Nuallain","year":"2010","unstructured":"O\u2019Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, et al. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci. 2010;30:14411\u20139.","journal-title":"J Neurosci"},{"key":"1788_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101339","volume":"68","author":"KI Avgerinos","year":"2021","unstructured":"Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer\u2019s disease. Ageing Res Rev. 2021;68: 101339.","journal-title":"Ageing Res Rev"},{"key":"1788_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3233\/JAD-230164","volume":"93","author":"V Volloch","year":"2023","unstructured":"Volloch V, Rits-Volloch S. Effect of Lecanemab in early Alzheimer\u2019s disease: mechanistic interpretation in the amyloid cascade hypothesis 2.0 perspective. J Alzheimers Dis. 2023;93:1277\u201384.","journal-title":"J Alzheimers Dis."},{"key":"1788_CR7","first-page":"759","volume":"13","author":"F Zemek","year":"2014","unstructured":"Zemek F, Drtinova L, Nepovimova E, Sepsova V, Korabecny J, Klimes J, et al. Outcomes of Alzheimer\u2019s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf. 2014;13:759\u201374.","journal-title":"Expert Opin Drug Saf"},{"key":"1788_CR8","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1586\/14737175.8.11.1703","volume":"8","author":"EJ Mufson","year":"2008","unstructured":"Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer\u2019s disease: therapeutic implications. Expert Rev Neurother. 2008;8:1703\u201318.","journal-title":"Expert Rev Neurother"},{"key":"1788_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40265-023-01851-2","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Lecanemab: first approval. Drugs. 2023;83:359\u201365.","journal-title":"Drugs"},{"key":"1788_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/21507740.2022.2048721","author":"T Daly","year":"2022","unstructured":"Daly T, Epelbaum S. The accelerated approval of Aducanumab invites a rethink of the current model of drug development for Alzheimer\u2019s disease. AJOB Neurosci. 2022. https:\/\/doi.org\/10.1080\/21507740.2022.2048721.","journal-title":"AJOB Neurosci"},{"key":"1788_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"1788_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/d41586-023-00393-7","volume":"615","author":"EM Reiman","year":"2023","unstructured":"Reiman EM. Drug trial for Alzheimer\u2019s disease is a game changer. Nature. 2023;615:42\u20133.","journal-title":"Nature"},{"key":"1788_CR13","unstructured":"FDA Converts Novel Alzheimer\u2019s Disease Treatment to Traditional Approval. FDA NEWS RELEASE, 2023."},{"key":"1788_CR14","volume":"14","author":"E Chin","year":"2022","unstructured":"Chin E, Jaqua E, Safaeipour M, Ladue T. Conventional versus new treatment: comparing the effects of acetylcholinesterase inhibitors and N-Methyl-D-aspartate receptor antagonist with aducanumab. Cureus. 2022;14: e31065.","journal-title":"Cureus"},{"key":"1788_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"1788_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12213","volume":"17","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021;17:696\u2013701.","journal-title":"Alzheimers Dement"},{"key":"1788_CR17","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"1788_CR18","doi-asserted-by":"publisher","first-page":"e2092","DOI":"10.1212\/WNL.0000000000201019","volume":"99","author":"SY Jeong","year":"2022","unstructured":"Jeong SY, Suh CH, Shim WH, Lim JS, Lee JH, Kim SJ. Incidence of amyloid-related imaging abnormalities in patients With Alzheimer disease treated with anti-beta-amyloid immunotherapy: a meta-analysis. Neurology. 2022;99:e2092\u2013101.","journal-title":"Neurology"},{"key":"1788_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.neurol.2022.06.012","volume":"178","author":"N Villain","year":"2022","unstructured":"Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer\u2019s disease Part 1: meta-analysis and review of efficacy and safety data, and medico-economical aspects. Rev Neurol. 2022;178:1011\u201330.","journal-title":"Rev Neurol"},{"key":"1788_CR20","first-page":"1613","volume":"27","author":"PG Synnott","year":"2021","unstructured":"Synnott PG, Whittington MD, Lin GA, Rind DM, Pearson SD. The effectiveness and value of aducanumab for Alzheimer\u2019s disease. J Manag Care Spec Pharm. 2021;27:1613\u20137.","journal-title":"J Manag Care Spec Pharm"},{"key":"1788_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12382","volume":"9","author":"Y Wang","year":"2023","unstructured":"Wang Y. An insider\u2019s perspective on FDA approval of aducanumab. Alzheimers Dement (N Y). 2023;9: e12382.","journal-title":"Alzheimers Dement (N Y)"},{"key":"1788_CR22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","volume":"103","author":"H Englund","year":"2007","unstructured":"Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103:334\u201345.","journal-title":"J Neurochem"},{"key":"1788_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","volume":"36","author":"A Lord","year":"2009","unstructured":"Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, Soderberg L, et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2009;36:425\u201334.","journal-title":"Neurobiol Dis"},{"key":"1788_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3233\/JAD-140741","volume":"43","author":"S Tucker","year":"2015","unstructured":"Tucker S, Moller C, Tegerstedt K, Lord A, Laudon H, Sjodahl J, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43:575\u201388.","journal-title":"J Alzheimers Dis"},{"key":"1788_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12974-018-1134-4","volume":"15","author":"S Sollvander","year":"2018","unstructured":"Sollvander S, Nikitidou E, Gallasch L, Zysk M, Soderberg L, Sehlin D, et al. The Abeta protofibril selective antibody mAb158 prevents accumulation of Abeta in astrocytes and rescues neurons from Abeta-induced cell death. J Neuroinflammation. 2018;15:98.","journal-title":"J Neuroinflammation"},{"key":"1788_CR26","unstructured":"Lecanemab Sweeps Up Toxic A\u03b2 Protofibrils, Catches Eyes of Trialists. ALZFORUM: ALZFORUM, 2021."},{"key":"1788_CR27","unstructured":"Short A\u03b2 Fibrils Easily Isolated from Alzheimer's Brain Fluid. ALZFORUM: ALZFORUM, 2022."},{"key":"1788_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2021.103641","volume":"114","author":"M Johannesson","year":"2021","unstructured":"Johannesson M, Sahlin C, Soderberg L, Basun H, Falting J, Moller C, et al. Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer\u2019s disease. Mol Cell Neurosci. 2021;114: 103641.","journal-title":"Mol Cell Neurosci"},{"key":"1788_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40035-021-00258-x","volume":"10","author":"F Rofo","year":"2021","unstructured":"Rofo F, Buijs J, Falk R, Honek K, Lannfelt L, Lilja AM, et al. Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. Transl Neurodegener. 2021;10:38.","journal-title":"Transl Neurodegener"},{"key":"1788_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","volume":"8","author":"V Logovinsky","year":"2016","unstructured":"Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, et al. Safety and tolerability of BAN2401\u2013a clinical study in Alzheimer\u2019s disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. 2016;8:14.","journal-title":"Alzheimers Res Ther"},{"key":"1788_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021;13:80.","journal-title":"Alzheimers Res Ther"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-023-01788-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-023-01788-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-023-01788-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T10:45:30Z","timestamp":1703155530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-023-01788-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1007\/s00011-023-01788-y","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}